4D Molecular Therapeutics Investor Day 2026 - 4D MOLECULAR THERAPEUTICS INC

Financial Performance:

• No specific GAAP financial results (revenue, EPS, cash flow) disclosed as the company is a pre-revenue clinical-stage biotech; the call focused on a $16 billion global wet AMD/DME market opportunity (60% in US).
• Current financial position described as "strong" with a cash runway extending into the second half of 2028.
• Commercial model relies on the "buy-and-build" reimbursement structure (Medicare Part B), where clinics purchase the drug and bill payers, potentially capturing full lifetime value upfront with a single injection to mitigate current "value erosion" caused by patient drop-off.

Guidance and Future Outlook:

• Pivotal Readouts: Forefront 1 (North American, treatment-naive) results expected in Q1/Q2 2027; Forefront 2 (Global, mixed treatment history) results expected in H2 2027.
• Commercialization: Regulatory alignment achieved (FDA RMAT, EMA Prime). Expected launch and adoption to begin with high-need patients, broadening to the full market over a 3-5 year horizon contingent on safety data and permanent J-code reimbursement (estimated 9 months post-approval).
• Long-term Vision: To establish 4150 as a "backbone therapy" offering continuous disease control for the lifetime of the patient after a single routine injection, potentially rendering patients injection-free.

Business Segments and Product Lines:

• Lead Asset (4D150): An intravitreal gene therapy vector delivering a fusion protein (flicrocept) and RNAi targeting four VEGF family members.
• Clinical Pipeline:
  • PRISM: Phase 1/2 study showing durable efficacy, anatomical stability, and significant treatment burden reduction (78% reduction vs. aflibercept; 87% in recently diagnosed) over two years with a favorable safety profile (transient inflammation).
  • Forefront: Two Phase 3 trials designed to demonstrate non-inferiority in Best Corrected Visual Acuity (BCVA) vs. aflibercept every 8 weeks in treatment-naive and treatment-experienced populations.
• Target Product Profile: Single in-office injection, 20-week corticosteroid taper to manage inflammation, potential for lifelong vision preservation and reduced treatment burden.

Market and Competitive Landscape:

• Market Size: US wet AMD/DME market growing to ~1.7 million treated eyes by 2030; 600,000 current patients with 160,000 new initiations annually.
• Competitive Gap: Current market dominated by episodic bolus anti-VEGFs (e.g., aflibercept, brolucizumab) which fail to provide continuous disease control, leading to vision loss during treatment gaps. Even newer long-acting agents only extend treatment intervals by ~12 days.
• Differentiation: 4D150 is positioned as the only candidate offering potential "backbone" continuous therapy via a non-surgical intravitreal injection, addressing the 40% real-world patient drop-out rate associated with current regimens.

Risks and Challenges:

• Safety: Potential for intraocular inflammation managed via a 20-week topical steroid taper; concerns regarding steroid-induced cataracts (viewed by physicians as manageable/inevitable compared to vision loss) and pressure spikes.
• Operational: Need to demonstrate safety and efficacy to gain payer confidence and reimbursement codes (J-code) for commercial success.
• Adoption Barriers: Initial uptake may be limited to high-need patients or those with specific insurance coverage (Medicare Advantage vs. Fee-for-Service) until data solidifies and reimbursement processes mature.
• Regulatory: Dependence on successful Phase 3 readouts in 2027 for approval; regulatory agencies require fellow-eye studies for bilateral treatment.

Management Commentary and Tone:

• Tone: Highly confident and optimistic; management emphasizes a "paradigm shift" from episodic to continuous care.
• Key Messages: 4D150 is designed to solve the "mismatch" between chronic disease biology and intermittent bolus treatment. Management asserts strong alignment among all stakeholders (patients, retina specialists, payers) for broad adoption.
• Strategic Confidence: CEO and medical team express certainty in the Phase 3 design, citing optimized response criteria and patient selection to maximize visual outcomes.

Analyst Questions and Answers:

• BCVA Expectations: Expected visual acuity gain of 6-8 letters at Week 52 for treatment-naive patients, with analysis comparing Week -5 (first injection) to standard market trials.
• Screening/Criteria: Response criteria (15% fluid reduction) are not expected to screen out a large volume of patients but will exclude those with high disease activity likely to fail (outliers), protecting the primary endpoint.
• Bilateral Dosing: FDA requires fellow-eye studies; 4D150 is expected to be approved for bilateral treatment, with physicians likely treating the fellow eye 1-6 months after the first eye's steroid taper concludes.
• Steroid Management: 20-week topical steroid taper is considered manageable; cataract progression is not viewed as a contraindication given the priority of macular preservation.
• Adoption Trajectory: Initial 1-year adoption focused on high-need patients (25% of market) and Medicare Fee-for-Service; broader adoption anticipated in Years 2-5 as reimbursement codes solidify and patient demand drives volume.

Other Key Points:

• Patient Stories: Highlighted patient "Judy's" emotional connection to independence and fear of vision loss, underscoring the high demand for reduced treatment burden.
• Clinical Site Insights: KOLs noted that real-world clinics are capacity-constrained (100+ patients/day) and heavily impacted by patient attrition, making a long-duration therapy operationally attractive to offset "value erosion."
• Manufacturing/Commercial: The team includes veterans from Genentech and previous commercial launches, with a strategy to integrate 4D150 into existing "buy-and-build" clinic workflows without requiring new infrastructure or surgery.